Related Experiment Videos
[Dihydralazine-induced acute hepatitis with IgM deficiency]
Schweizerische Medizinische Wochenschrift
|May 14, 1977
Summary
Two patients with immunoglobulin M (IgM)-deficiency experienced recurrent hepatitis after taking dihydralazine. This suggests a potential link between the drug and liver disease in individuals with IgM-deficiency.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Immunoglobulin M (IgM)-deficiency is a primary immunodeficiency.
- Drug-induced liver injury (DILI) is a significant clinical concern.
- Hepatitis B surface antigen (HB3-Ag) negative hepatitis requires differential diagnosis.
Observation:
- Two patients with IgM-deficiency presented with acute, recurrent hepatitis.
- Hepatitis occurred after ingestion of low daily doses of dihydralazine.
- Liver histology showed bridging necrosis.
Findings:
- The hepatitis was HB3-Ag negative.
- Antimitochondrial antibodies (AMA) and anti-smooth muscle antibodies (ASMA) were detected in one patient each.
- Recurrence of hepatitis after dihydralazine re-exposure suggests a probable drug association.
Implications:
- This case series highlights a potential association between dihydralazine and hepatitis in patients with IgM-deficiency.
- Further investigation is warranted to understand the mechanism of dihydralazine-induced liver injury in this population.
- Screening for drug hypersensitivity and liver disease in IgM-deficient patients may be beneficial.